21 completed, 9 unknown, 3 withdrawn, 2 active not recruiting. 15 Phase 4, 7 Not applicable, 7 Phase 2, 6 Phase 3, 5 Phase 1.
Follow Clonazepam: new trials by email Literature Review of Clonazepam trials Research Report on Clonazepam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Management of Catatonic Features in Adolescents With Profound Autism Intranasal Midazolam (Benzodiazepine Challenge Test), Oral Clonazepam, Electroconvulsive Therapy (ECT) - Autism Spectrum Disorder, Catatonia | Not applicable | Active not recruiting | Tanta University | 30 | 2026-01-01 | 2026-03-27 |
| Bioequivalence Study of Clonazepam 2 Mg Tablets Rivotril®, Clonazepam TQ 2 mg - Healthy, Healthy Donors | Phase 4 | Not yet recruiting | Centro de Atencion e Investigacion Medica | 24 | 2025-06-10 | 2025-03-10 |
| Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),, Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,, Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine - Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder | Phase 4 | Active not recruiting | Dr. Stavroula Rakitzi | 84 | 2025-06-04 | 2026-05-01 |
| Enhancing Mobility and Mental Health in Dementia Patients Exercise, Clonazepam - Dementia | Not applicable | Unknown | Oxleas NHS Foundation Trust | 6 | 2025-01-06 | 2024-09-24 |
| Psychopharmacological Treatment of Emotional Distress Clonazepam, Olanzapine, Buprenorphine - Suicide Crisis Syndrome, Psychological Distress | Phase 4 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2024-03-13 | 2026-07-28 | |
| Detoxification From the Lipid Tract electroencephalogram biofeedback, electrical brain stimulation, ultra-low frequency transcranial magnetic stimulation - COVID-19 Vaccine Adverse Reaction | Phase 4 | Completed | Pachankis, Yang I., M.D. | 1 | 2024-02-26 | 2024-04-10 |
| Efficacy of Hydroxyzine for Patients With Panic Disorder Hydroxyzine, Escitalopram Oxalate - Panic Disorder | Phase 4 | Not yet recruiting | Sultan Qaboos University | 80 | 2023-12-30 | 2023-02-21 |
| Benzodiazepine Study for the Treatment of Seizure Clusters in a Third Level Mexican Neurological Center Midazolam oral solution, ClonazePAM Oral Product, Usual medication/ traditional - Cluster Seizure | Not applicable | Unknown | El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez | 150 | 2023-05-01 | 2024-05-31 |
| Inflammatory Markers in Saliva of Patients With Burning Mouth Syndrome Laser+clonazepam, Laser Sham, Laser - Burning Mouth Syndrome | Not applicable | Completed | Universidad de Murcia | 20 | 2022-01-10 | 2024-07-31 |
| Burning Mouth Syndrome - New Diagnostic Criteria and Treatment Clonazepam 0.5 MG, Capsaicin Topical, Placebo - Burning Mouth Syndrome | Not applicable | Unknown | Malmö University | 40 | 2021-11-01 | 2021-09-28 |
| Single Dose of Clonazepam Versus Intermiittent Diazepam for Febrile Seizures Prevention Clonazepam 0.5 MG, Diazepam Tablets - Recurrent Febrile Convulsion | Not applicable | Unknown | Queen Sirikit National Institute of Child Health | 74 | 2020-05-13 | 2021-08-30 |
| Low Level Laser Therapy Plus Topical Clonazepam Treatment to Burning Mouth Symdrome low level laser therapy plus topical clonazepam, Sham laser plus topical clonazepam, Active laser plus placebo of topical clonazepam - Burning Mouth Syndrome | Phase 4 | Unknown | Universidad Nacional Autonoma de Mexico | 27 | 2019-08-16 | 2020-03-18 |
| Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome Clonazepam tablets, tongue pads - Burning Mouth Syndrome, Glossodynia | Phase 2 | Completed | Wroclaw Medical University | 58 | 2019-01-12 | 2021-07-22 |
| Efficacy and Safety of Melatonin and Clonazepam for IRBD Melatonin 2mg, ClonazePAM 0.5 MG - REM Sleep Behavior Disorder | Not applicable | Completed | Kyung Hee University Hospital at Gangdong | 34 | 2017-11-09 | 2021-02-21 |
| Exploring the Role of the GABAergic Modulation in Pain Transmission in Human NDMC 20mg, NDMC60mg, Clonazepam 1.5mg - Neuropathic Pain | Phase 1 | Completed | Jules Desmeules | 56 | 2017-03-30 | 2019-04-19 |
| Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients Clonazepam, Placebo - Cannabis Use Disorder | Phase 2 | Completed | New York State Psychiatric Institute | 68 | 2016-12-01 | 2021-08-06 |
| Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia Clonazepam, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 4 | Withdrawn | Palo Alto Veterans Institute for Research | 2016-10-01 | 2018-04-05 | |
| Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease Melatonin PR, Clonazepam, Melatonin PR placebo - REM Sleep Behavior Disorder, Parkinson Disease | Phase 2 | Unknown | Seoul National University Hospital | 30 | 2016-07-01 | 2016-06-03 |
| Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome Clonazepam mixed with Mucolox®, Mucolox® alone, Clonazepam - Burning Mouth Syndrome | Phase 4 | Withdrawn | University of Alberta | 2016-04-01 | 2018-05-03 | |
| Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism Clonazepam, Placebo - REM Sleep Behavior Disorder | Phase 2 | Completed | Seoul National University Hospital | 40 | 2015-03-01 | 2016-04-25 |
Showing 20 of 39. Sign in to see all of them.
Burning Mouth Syndrome (6) · Epilepsy (5) · Neuralgia (3) · Pain (3) · Panic Disorder (3) · REM Sleep Behavior Disorder (3) · Anxiety Disorders (2) · Chronic Pain (2) · Dementia (2) · Depression (2) · Fasting (2) · Parkinson Disease (2) · Schizophrenia (2) · Status Epilepticus (2) · Agoraphobia (1)
Assistance Publique - Hôpitaux de Paris (2) · Massachusetts General Hospital (2) · Par Pharmaceutical, Inc. (2) · Seoul National University Hospital (2) · Centro de Atencion e Investigacion Medica (1) · Dr. Stavroula Rakitzi (1) · El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez (1) · Hannover Medical School (1) · Icahn School of Medicine at Mount Sinai (1) · Insel Gruppe AG, University Hospital Bern (1) · Jazz Pharmaceuticals (1) · Jules Desmeules (1) · Kyung Hee University Hospital at Gangdong (1) · Malmö University (1) · National Institute of Mental Health (NIMH) (1)
United States (8) · South Korea (4) · Mexico (3) · Switzerland (3) · China (2) · France (2) · United Kingdom (2) · Brazil (1) · Canada (1) · Egypt (1) · Finland (1) · Germany (1) · Greece (1) · Poland (1) · Spain (1)
Gary Shillito (2) · Ali Ziaee (1) · Beom Seok Jeon, MD, Ph.D (1) · Beomseok Jeon, MD, PhD (1) · Beverly Benson, PhD (1) · Dr. Polyxeni Georgila, M. D. (1) · Dr. Stavroula Rakitzi, PhD (1) · Helen Cross, FRCP(UK) (1) · Helge Frieling, Prof., MD (1) · Igor Galynker, MD,PhD (1) · Irwin Plisco (1) · Jinjutha Nithiuthai, MD (1) · John Mariani, MD (1)
PMID 15109507, PMID 19125841, PMID 19814948, PMID 21093630, PMID 21344132, PMID 21364347, PMID 21967362, PMID 22198456, PMID 22238700, PMID 22344742, PMID 23554851, PMID 24399428, PMID 26359814, PMID 26535101, PMID 26627366, PMID 26873501, PMID 27302545, PMID 27737361, PMID 27893167, PMID 27919663, PMID 28225210, PMID 28446244, PMID 30386416, PMID 31044001, PMID 35141811, PMID 3907504, PMID 8510706
K23MH001831 (1), R01MH070919 (1), U54DA037842 (1)